| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Inhibition of mutated, activated BRAF in metastatic melanoma.
|
N Engl J Med
|
2010
|
36.57
|
|
2
|
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
|
Nature
|
2010
|
16.12
|
|
3
|
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
|
N Engl J Med
|
2012
|
13.48
|
|
4
|
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
|
N Engl J Med
|
2012
|
13.17
|
|
5
|
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
|
J Clin Oncol
|
2014
|
9.86
|
|
6
|
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
|
N Engl J Med
|
2012
|
6.93
|
|
7
|
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.
|
Lancet Oncol
|
2012
|
5.32
|
|
8
|
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
|
N Engl J Med
|
2015
|
4.78
|
|
9
|
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.
|
Lancet Oncol
|
2012
|
3.71
|
|
10
|
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
|
J Clin Oncol
|
2008
|
3.58
|
|
11
|
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.
|
J Clin Oncol
|
2009
|
2.63
|
|
12
|
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
|
J Clin Oncol
|
2013
|
2.51
|
|
13
|
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
|
Oncologist
|
2008
|
2.22
|
|
14
|
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.
|
J Clin Oncol
|
2012
|
2.21
|
|
15
|
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.
|
N Engl J Med
|
2015
|
1.75
|
|
16
|
BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.
|
Clin Cancer Res
|
2013
|
1.66
|
|
17
|
Opportunities and obstacles to combination targeted therapy in renal cell cancer.
|
Clin Cancer Res
|
2007
|
1.57
|
|
18
|
Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy.
|
Cancer
|
2012
|
1.54
|
|
19
|
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study.
|
J Immunother
|
2013
|
1.48
|
|
20
|
Molecular targets in melanoma from angiogenesis to apoptosis.
|
Clin Cancer Res
|
2006
|
1.30
|
|
21
|
Combination targeted therapy in advanced renal cell carcinoma.
|
Cancer
|
2009
|
1.24
|
|
22
|
γ-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from 2 phase I clinical trials of SJG-136 (SG2000).
|
Clin Cancer Res
|
2012
|
1.02
|
|
23
|
Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study.
|
J Mass Spectrom
|
2008
|
1.00
|
|
24
|
A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
|
Clin Cancer Res
|
2009
|
0.98
|
|
25
|
B-RAF inhibitors: an evolving role in the therapy of malignant melanoma.
|
Curr Oncol Rep
|
2010
|
0.97
|
|
26
|
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".
|
J Transl Med
|
2013
|
0.95
|
|
27
|
Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma.
|
J Immunother
|
2009
|
0.93
|
|
28
|
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.
|
Cancer
|
2014
|
0.90
|
|
29
|
Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma.
|
Head Neck
|
2010
|
0.88
|
|
30
|
Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
|
Clin Cancer Res
|
2012
|
0.87
|
|
31
|
Treatment of NRAS-mutant melanoma.
|
Curr Treat Options Oncol
|
2015
|
0.86
|
|
32
|
Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.
|
Future Oncol
|
2012
|
0.82
|
|
33
|
Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma.
|
Biochem Pharmacol
|
2010
|
0.80
|
|
34
|
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.
|
J Transl Med
|
2014
|
0.80
|
|
35
|
Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition.
|
J Immunother
|
2017
|
0.76
|
|
36
|
Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies.
|
Anticancer Drugs
|
2015
|
0.75
|
|
37
|
Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?
|
Oncologist
|
2012
|
0.75
|
|
38
|
Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.
|
Melanoma Res
|
2017
|
0.75
|
|
39
|
New Does Not Always Mean Better: Isolated Limb Perfusion Still Has a Role in the Management of In-Transit Melanoma Metastases.
|
Oncology (Williston Park)
|
2016
|
0.75
|